Quince Therapeutics Inc. recently presented at the H.C. Wainwright 27th Annual Global Investment Conference, highlighting their innovative approach to treating rare diseases. The company showcased its eDSP technology, which involves red blood cell encapsulated dexamethasone sodium phosphate, designed to provide corticosteroid efficacy without the associated toxicity. Quince Therapeutics has completed enrollment for the pivotal Phase 3 NEAT clinical trial targeting pediatric rare disease Ataxia-Telangiectasia (A-T), with a significant commercial opportunity of over $1 billion. Additionally, the company announced a strategic partnership with Option Care Health to support the administration of their lead asset, eDSP. Quince Therapeutics has also expressed a significant pipeline expansion opportunity for eDSP with Duchenne muscular dystrophy (DMD) and other rare immunology and autoimmune targets. The company is financially positioned to fund operations through the first quarter of 2026 and potentially further with exercised warrants. You can access the full presentation through the link below.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quince Therapeutics Inc. published the original content used to generate this news brief on September 09, 2025, and is solely responsible for the information contained therein.
Comments